Examiner Cite

No

Initial\*

5

Patent Number

Kind

publisher, city and/or country where published.

Code1

Issue Date

Remove

Figures Appear

Pages.Columns.Lines where

Relevant Passages or Relevant

Τ۶

	Application Number		10599334	
	Filing Date		2007-06-28	
NFORMATION DISCLOSURE TATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor Goto		0	
	Art Unit		1786	
	Examiner Name	BOHA	ATY, Andrew K.	
	Attorney Docket Numb	er	2150LT/100227	

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

	ľ										
If you wish	h to a	d additio	nal U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	_
				U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Cite No Publication Number Kind Code1 Date		ition	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear						
	1										
If you wisl	h to a	dd additio	nal U.S. Publi	shed Ap	plication	citation	ninformation	please click the Ad	d butto	on. Add	
					FOREIG	SN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Number	Document 3	Country Code <sup>2</sup>		Kind Code <sup>4</sup>		Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
	1										
If you wis	h to a	dd additio	nal Foreign P	atent Do	cument	citation	information p	lease click the Add	butto	n Add	_
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	_

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

Examiner Cite

Initials\* No

	Application Number		10599334	
	Filing Date		2007-06-28	
INFORMATION DISCLOSURE	First Named Inventor	Goto		
STATEMENT BY APPLICANT  ( Not for submission under 37 CFR 1.99)	Art Unit		1786	
(Not lot sasimission ander or or trissy	Examiner Name	BOH/	ATY, Andrew K.	
	Attorney Docket Numb	er	2150LT/100227	

1	BALDWIN, ROGER A, et al., Arylenebis (tertiary phosphines) and - (phosphinic acids), The Journal of Organic Chemistry, May 1967, 32 (5), 1572-1577	
2	BALDWIN, ROGER AL., et at, Organometallic Azides, I. Preparation and Reactions of Diarylphosphnic Azides, The Journal of Organic Chemistry, November 1965, 30 (11), 3860-3866	

EXAMINER SIGNATURE

Examiner Signature

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include coav of this form with next communication to applicant.

See Knd Oodes of USPTO Patent Documents at <u>www.USPTO.GDY</u> or MPEP 901 (M. <sup>2</sup> Entire office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>2</sup> For Japanese patent documents, the advisable of the year of the eign of the Empire or must precise the senior in order of the patent document. Program to the patent of the patent document. Empire language strategies an adduction.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10599334	
	Filing Date		2007-06-28	
	First Named Inventor	Goto	Goto	
Art Unit			1786	
	Examiner Name	BOHA	ATY, Andrew K	
	Attorney Docket Number		2150LT/100227	

## CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFR 197(e/11).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

## SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Richard S. Myers/	Date (YYYY-MM-DD) 2011-12-08			
Name/Print	Richard S. Myers, Jr.	Registration Number	42022		

This collection of information is required by 3T CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary (Tifice, U.S. perpartment of Commence, P. 0 Box 1445), Alexandria, V.3.2311-1450. DIN OTS END FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.2311-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the sublect matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursyant to 5 U.S.C. S52a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of
  the application presume to 58 U.S. C. 12(p) or issuance of a patent pursuant to 58 U.S. C. 151. Further, a record
  may be disclosed, subject to the limitations of 37 CFR 11, 4s as routine use, to the public if the record was filed in
  an application which became abandoned or in which the proceedings were terminated and which application is
  referenced by whither a published application is application open to public inscredions or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.